Literature DB >> 8614990

The HBV-producing cell line HepG2-4A5: a new in vitro system for studying the regulation of HBV replication and for screening anti-hepatitis B virus drugs.

L Weiss1, A S Kekulè, U Jakubowski, E Bürgelt, P H Hofschneider.   

Abstract

All tissue culture systems for propagating HBV employed so far make use of tandemly arranged HBV genomes usually under the control of strong foreign promoters. Thus these systems are helpful for virus production but are of limited value in the investigation of the regulation of HBV replication or of the extent to which the expression of viral genes might be influenced by cellular signal transduction pathways. To overcome this barrier we established an HBV-producing cell line (HepG2-4A5) by stably transfecting HepG2 cells with a replication-competent, terminally redundant HBV plasmid (pSPT1.2 xHBV) that contains each of the four major HBV-ORFs only once and exclusively under the control of their own regulatory elements. HepG2-4A5 cells contain a single, nonrearranged, chromosomally integrated, replication-competent HBV genome. In the cytoplasm of HepG2-4A5 cells, all typical viral mRNAs were detectable, but no other viral transcripts were found. Furthermore, all viral gene products are synthesized in a balanced ratio, as close as possible to that found in an in vivo infection. Dane-like particles released from HepG2-4A5 cells were indistinguishable from virions synthesized in vivo, by all physical (electron microscopy, buoyant density) and biochemical (endogenous polymerase reaction, immunogenic behaviour) criteria. Because of the autologous genome organization in this system, the HepG2-4A5 cell line allows studies on the function of the HBV gene products with respect to their involvement in regulating HBV replication under conditions imitating as closely as possible the situation in vivo. Furthermore, this cell line might be a helpful tool in screening antiviral drugs and in studying their effect on regulating HBV replication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8614990     DOI: 10.1006/viro.1996.0049

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Changes in the antigenicity of a hepatitis B virus mutant stemming from lamivudine therapy.

Authors:  W N Chen; C J Oon
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Hepatitis B virus surface antigen (HBsAg) mutants in Singapore adults and vaccinated children with high anti-hepatitis B virus antibody levels but negative for HBsAg.

Authors:  W N Chen; C J Oon
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

4.  Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus.

Authors:  Manujendra N Saha; Atsushi Tanaka; Atsushi Jinno-Oue; Nobuaki Shimizu; Kazushi Tamura; Masahiko Shinagawa; Joe Chiba; Hiroo Hoshino
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Presence of replicating virus in recombinant hepadnavirus stocks results from recombination and can be eliminated by the use of a packaging cell line.

Authors:  Uta Klöcker; Heike Oberwinkler; Timo Kürschner; Ulrike Protzer
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  The rate of hepatitis C virus infection initiation in vitro is directly related to particle density.

Authors:  Ali Sabahi; Katherine A Marsh; Harel Dahari; Peter Corcoran; Jennifer M Lamora; Xuemei Yu; Robert F Garry; Susan L Uprichard
Journal:  Virology       Date:  2010-08-25       Impact factor: 3.616

7.  Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein.

Authors:  Henrik Daub; Stephanie Blencke; Peter Habenberger; Alexander Kurtenbach; Julia Dennenmoser; Josef Wissing; Axel Ullrich; Matt Cotten
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 8.  Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions.

Authors:  Yongzhen Liu; Stephanie Maya; Alexander Ploss
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

9.  Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication.

Authors:  Lisa F P Ng; Marieta Chan; Soh-Ha Chan; Paul Chung-Pui Cheng; Eastwood Hon-Chiu Leung; Wei-Ning Chen; Ee-Chee Ren
Journal:  PLoS Med       Date:  2005-07-26       Impact factor: 11.069

10.  An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection.

Authors:  Chih-Lang Lin; Rong-Nan Chien; Shi-Ming Lin; Po-Yuan Ke; Chen-Chun Lin; Chau-Ting Yeh
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.